Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA1/TA2
| Agency: | DEPT OF DEFENSE |
|---|---|
| State: | Federal |
| Type of Government: | Federal |
| FSC Category: |
|
| NAICS Category: |
|
| Posted Date: | May 28, 2026 |
| Due Date: | Jun 24, 2026 |
| Solicitation No: | DARPA-PS-26-124 |
| Original Source: | Please Login to View Page |
| Contact information: | Please Login to View Page |
| Bid Documents: | Please Login to View Page |
Description
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
- Contract Opportunity Type: Solicitation (Updated)
- Updated Published Date: May 28, 2026 03:37 pm EDT
- Original Published Date: May 27, 2026 05:47 pm EDT
- Updated Date Offers Due: Jun 24, 2026 04:00 pm EDT
- Original Date Offers Due: Jun 24, 2026 04:00 pm EDT
- Inactive Policy: Manual
- Updated Inactive Date: Jul 24, 2026
- Original Inactive Date: Jul 24, 2026
-
Initiative:
- None
- Original Set Aside:
- Product Service Code: AC12 - NATIONAL DEFENSE R&D SERVICES; DEPARTMENT OF DEFENSE - MILITARY; APPLIED RESEARCH
-
NAICS Code:
- 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
-
Place of Performance:
The Resuscitation and Prevention of Ischemia-induced Dysfunction (RAPIID) program seeks to deliver a transformative, end-to-end resuscitation system that redefines far-forward trauma care. RAPIID aims for this system to be fieldable, usable, and scalable, providing a capability equivalent or superior to stored whole blood in early resuscitation while removing dependence on cold chain and donor logistics. RAPIID seeks to do this by developing a blood analog system (BAS) comprising sequentially administered blood analog components, integrated with ruggedized delivery formats, point-of-care diagnostics, and clinical practice guidelines (CPGs). To maximize post-program viability of developed products, RAPIID will develop and execute effective regulatory and commercialization strategies and accelerate advanced development through technology readiness level (TRL) 7 (Scale-up and Phase II Clinical Trials)1 for blood analog components and TRL 8 (Clinical Studies)2 for devices and diagnostics. This solicitation is to request proposals addressing ONLY Phase 1 of Task Area (TA)-1 and/or TA-2.
- 675 NORTH RANDOLPH STREET
- ARLINGTON , VA 222032114
- USA
- BAA Coordinator
- RAPIID@darpa.mil
- May 28, 2026 03:37 pm EDTSolicitation (Updated)
- May 27, 2026 05:47 pm EDT Solicitation (Original)
Related Document
| May 27, 2026 | [Solicitation (Original)] Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA1/TA2 |
See Also
Follow Code 34 Engineering Services for Electronic Warfare (EW) and Electromagnetic (EM) Special
DEPT OF DEFENSE
Due by 9/24/2026
Follow Environmental Security Technology Certification Program (ESTCP) - Energy and Environmental Technology Demonstrations
DEPT OF DEFENSE
Due by 8/20/2027
Follow Request for Information (RFI) USNIC SAR Data Active Contract Opportunity Notice ID
COMMERCE, DEPARTMENT OF
Due by 9/25/2026
Follow Defense Sciences Office (DSO) Office-wide BAA Active Contract Opportunity Notice ID HR001126S0015
DEPT OF DEFENSE
Due by 8/27/2027